Brooke Faught, NP
Nurse Practitioner · Nashville, TNNPI 1255316238
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,202 of the $86,894 with a category attached, or 70.4%. 36 manufacturers reported payments, led by Astellas Pharma US Inc at 43.1% of the total. Reporting peaked in 2023 at $29,122 and has fallen 60.7% since, to $11,437 in 2025. Among nurse practitioner clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $198.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$37K
- Agile Therapeutics, Inc.$25K
- Mayne Pharma Commercial LLC$8K
- Acella Pharmaceuticals, LLC$8K
- Bayer$2K
- Scynexis, Inc.$2K
- plus $4K from 30 others
Across 1 payment — averaging $2556.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Innovation$3K
What the payments were for
- Consulting fees$9,79011%
- Speaking & faculty fees$61,20270%
- Travel & lodging$8,1149%
- Food & beverage$7,0538%
- Education$7141%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 94 | $37,410 |
| Agile Therapeutics, Inc. | 59 | $24,525 |
| Mayne Pharma Commercial LLC | 20 | $8,218 |
| Acella Pharmaceuticals, LLC | 2 | $8,105 |
| Bayer | 2 | $2,207 |
| Scynexis, Inc. | 10 | $2,033 |
| Millicent US Inc | 18 | $536 |
| Myovant Sciences Inc. | 66 | $521 |
| AbbVie(2 entities) | 19 | $331 |
| Exeltis, USA Inc. | 7 | $272 |
| Idorsia Pharmaceuticals US Inc | 11 | $252 |
| Therapeuticsmd, Inc. | 12 | $251 |
| Laborie Medical Technologies Corp. | 5 | $249 |
| Sumitomo Pharma America, Inc. | 36 | $243 |
| Axonics, Inc. | 19 | $214 |
| Urovant Sciences Inc | 13 | $207 |
| Cosette Pharmaceuticals Inc. | 2 | $195 |
| Hologic Sales And Service, LLC | 1 | $150 |
| Novo Nordisk | 4 | $148 |
| Organon | 2 | $139 |
| Procept Biorobotics Corporation | 3 | $91 |
| Currax Pharmaceuticals LLC | 5 | $71 |
| Mycovia Pharmaceuticals, Inc. | 3 | $70 |
| Ascend Therapeutics US, LLC | 3 | $57 |
| Shield Therapeutics Inc | 3 | $57 |
| 180 Medical, Inc. | 2 | $46 |
| Myriad Genetic Laboratories, Inc. | 3 | $40 |
| Medtronic | 3 | $39 |
| AstraZeneca | 2 | $37 |
| Boston Scientific | 2 | $35 |
| Pfizer | 2 | $33 |
| Coopersurgical, Inc. | 1 | $31 |
| Biogen | 1 | $29 |
| Merck | 1 | $24 |
| Lilly USA, LLC | 1 | $16 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,894 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 18 | $14,809 |
| BijuvaEstradiol/Progesterone | 30 | $12,243 |
| OsphenaOspemifene | 12 | $7,522 |
| Estradiol (Twice Weekly)Estradiol | 19 | $1,884 |
| Estradiol | 34 | $1,749 |
| ProgesteroneProgesterone, Micronized | 29 | $1,640 |
| SynthroidLevothyroxine Sodium | 17 | $1,629 |
| Terconazole | 15 | $870 |
| Nystatin | 11 | $483 |
| Fluconazole | 63 | $472 |
| NitrofurantoinNitrofurantoin Macrocrystal | 14 | $402 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $392 |
| Montelukast Sodium | 15 | $273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $37,410 | $14,80918 claims |
| Therapeuticsmd, Inc.Bijuva | $251 | $12,24330 claims |
| AbbVieSynthroid | $331 | $1,62917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Nashville
- Susan UtleyNashville$194K
- Lauren WelchNashville$71K
- Patricia MorrisNashville$53K
- Molly MueckeNashville$30K
- Cherish HoltNashville$20K
- Virginia BradshawNashville$17K
- Bettina EnghNashville$17K
- Megan HuningNashville$12K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.